Latest Macrolide Stories

- Cempra to Host Conference Call and Webcast at 4:30 p.m. EDT, Today, May 13, 2013 - CHAPEL HILL, N.C., May 13, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical needs in the treatment of bacterial infections, today announced the signing of an exclusive license and development agreement for solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings...

Consumer questions about legal eligibilities to seek compensation over alleged serious side effects from use of popular antibiotic can be answered through free consultations offered by nationwide team of attorneys. San Diego, CA (PRWEB) April 28, 2013 http://www.resource4thepeople.com/defectivedrugs/Zithromax-lawsuits.html Resource4thePeople announced today that it is following up on the recent warning issued by the Food and Drug Administration concerning alleged links between the popular...

- Phase 2 study of patients with gonococcal infections shows 100 percent were treated successfully CHAPEL HILL, N.C., April 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin,...

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. David J. Serisier, M.B.B.S., D.M., F.R.A.C.P., of Mater Adult Hospital, South Brisbane, Australia, and colleagues tested the hypothesis that low-dose erythromycin would reduce pulmonary exacerbations in patients with non-CF...

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. Bronchiectasis is characterized by abnormal widening of the bronchi (air tubes that branch deep into the lungs) and can cause recurrent lung infections, a disabling cough, shortness of breath, and coughing up blood. "If...

Jason Pierce, MSN, MBA, RN for redOrbit.com – Your Universe Online A study published in the British Medical Journal is the first of its kind to link the use of the antibiotic clarithromycin for treatment of chronic obstructive pulmonary disease (COPD) and community acquired pneumonia with an increased risk of death related to heart problems long after the course of treatment. Previous studies have suggested the risk of heart related mortality may increase during the use of the drug, but...

redOrbit Staff & Wire Reports - Your Universe Online A commonly-prescribed antibiotic could trigger potentially fatal irregular heart rhythms in some patients, officials from the US Food and Drug Administration (FDA) warned on Tuesday. Azithromycin, which is commonly sold as Zithromax or Zmax and is sometimes referred to as a “Z-Pack,” could cause the condition in patients who have an elevated risk of developing cardiovascular problems, reports Deborah Kotz of the Boston Globe....

CHAPEL HILL, N.C., Feb. 12, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the National Institute of Allergy and Infectious Diseases (NIAID) awarded a grant to Richard C. Boucher, M.D., Kenan Professor of Medicine and director of the Cystic Fibrosis and Pulmonary Research and Treatment Center...

SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data show continued differentiation of the company's fourth-generation macrolide/fluoroketolide, solithromycin, from currently available macrolides. The data will be presented at the IDWeek 2012(TM) conference on Oct. 17- 21 in San Diego....

(Ivanhoe Newswire) --It’s been used to treat pneumonia, strep and sinusitis and now one of the world’s best-selling antibiotics is providing relief to lung transplant patients too. Researchers in the UK say azithromycin can be an effective treatment option for patients suffering from bronchiolitis obliterans syndrome (BOS), which is a potentially deadly complication that occurs in the majority of patients following lung transplantation. BOS occurs in part when the body rejects the...